Previous 10 | Next 10 |
SilverBow Resorces Inc. (SBOW) is expected to report $2.36 for Q4 2023 FAT Brands Inc. Class B Common Stock (FATBB) is expected to report for quarter end 2023-12-31 Ecovyst Inc. (ECVT) is expected to report $0.2 for Q4 2023 MYR Group Inc. (MYRG) is expected to report $1.41 for Q4 2023...
2024-02-27 12:43:51 ET A California-based %Biotech company is turning heads during Tuesday’s session after the company announced it entered into an exclusive licensing agreement for newly engineered double-stranded DNA ligase with Roche, according to a press release. Shares o...
2024-02-27 09:06:36 ET DENVER, Colo., Feb 27, 2024 ( 247marketnews.com )- The following companies are mentioned; Codexis (NASDAQ: CDXS ), Kraig Biocraft Laboratories (OTCQB: KBLB ), Janux Therapeutics (NASDAQ: JANX ), TransMedics Group (NASDAQ: TMDX ), and Viking Therape...
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an agreement with Roche for an exclusive, global license for the Company’s newly engineered double-stranded DNA (dsDNA) ligase for...
REDWOOD CITY, Calif., Feb. 26, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the Company will attend the TD Cowen 44 th Annual Health Care Conference, being held March 4-6, 2024, in Boston, Massachusetts. Management will par...
REDWOOD CITY, Calif., Feb. 20, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced the appointment of Masad Damha, PhD, and Jim Lalonde, PhD, to the Company’s Strategic Advisory Board (SAB), joining John Maraganore, PhD, the founder ...
REDWOOD CITY, Calif., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the fourth quarter and fiscal year 2023 on Wednesday, February 28, 2024, following the close of market. Codexis...
2024-02-13 16:12:15 ET More on Codexis Codexis and Aldevron sign exclusive licensing deal for Codex HiCap RNA polymerase Seeking Alpha’s Quant Rating on Codexis Read the full article on Seeking Alpha For further details see: Codexis gets $40M finan...
Term loan agreement enables Company to accelerate development and enhance commercialization of ECO Synthesis™ manufacturing platform for RNAi therapeutics Financing bolsters cash position and provides additional flexibility on projected runway through positive cash-flow aro...
2024-02-01 17:56:16 ET Gainers: Meta Platforms ( META ) +14% . Amazon ( AMZN ) +8% . Codexis ( CDXS ) +5% . Sutro Biopharma ( STRO ) +5% . Kulicke and Soffa Industries ( KLIC ) +5% . Losers: Atlassian Corporation ( TEAM...
News, Short Squeeze, Breakout and More Instantly...
REDWOOD CITY, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced that it will report its financial results for the second quarter of 2024 on Thursday, August 8, 2024, following the close of market. Codexis management will ...
REDWOOD CITY, Calif., July 01, 2024 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company, today announced it has entered into an asset purchase agreement with Crosswalk Therapeutics for the Company’s investigational Fabry and Pompe disease compounds. Under...
2024-05-30 07:30:04 ET Cantor Fitzgerald analyst issues OVERWEIGHT recommendation for CDXS on May 30, 2024 06:15AM ET. CDXS was trading at $3.19 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy rec...